Company news

Some AstraZeneca oncology sales force personnel will be shifted to other product lines in anticipation of patent expirations. Arimidex, used for the treatment of breast cancer, will be going off patent in 2010, and Casodex, for prostate cancer, is scheduled to go off patent in 2009. A company spokesperson said while most of the oncology sales reps will be reassigned, some will be let go through attrition.
 
Wyeth has entered into acquisition talks with Crucell, a Dutch vaccine manufacturer, according to a Wall Street Journal report. Wyeth may offer as much as $1.35 billion, the report said. Crucell manufactures vaccines for hepatitis B, influenza, typhoid and cholera. 
 
Reuters reported that Icelandic company Actavis, one of the world's top generic drug manufacturers, will be auctioned off by its private-equity owners. The auction could raise as much as $6 billion or more, according to the Reuters report.
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.